Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma": [Ann Oncol 35 (2024) 1039-1047].
Kim TM, Taszner M, Novelli S, Cho SG, Villasboas JC, Merli M, Jiménez-Ubieto A, Tessoulin B, Poon LM, Tucker D, Walewski J, Yi S, Song Y, Chong G, Bachy E, Guidez S, Alonso A, Jagadeesh D, Zhang W, Magnano L, Iskierka-Jażdżwska E, Tani M, Shen B, Uppala A, Zhu M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Luminari S; ELM-2 Investigators. Kim TM, et al. Among authors: jimenez ubieto a. Ann Oncol. 2024 Dec 2:S0923-7534(24)04945-7. doi: 10.1016/j.annonc.2024.11.009. Online ahead of print. Ann Oncol. 2024. PMID: 39627085 Free article. No abstract available.
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma.
Kim TM, Taszner M, Novelli S, Cho SG, Villasboas JC, Merli M, Jiménez-Ubieto A, Tessoulin B, Poon LM, Tucker D, Walewski J, Yi S, Song Y, Chong G, Bachy E, Guidez S, Alonso A, Jagadeesh D, Zhang W, Magnano L, Iskierka-Jażdżewska E, Tani M, Shen B, Uppala A, Zhu M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Luminari S; ELM-2 Investigators. Kim TM, et al. Among authors: jimenez ubieto a. Ann Oncol. 2024 Nov;35(11):1039-1047. doi: 10.1016/j.annonc.2024.08.2239. Epub 2024 Aug 13. Ann Oncol. 2024. PMID: 39147364 Free article. Clinical Trial.
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group.
Rey-Búa B, Grande C, Sánchez Blanco JJ, Abrisqueta P, Gutiérrez A, Ramírez Páyer Á, Giné E, Zeberio Etxetxipia I, Terol MJ, de la Cruz Vicente F, Andreu R, Ramirez MJ, de la Fuente A, Viguria MC, Peñarrubia MJ, Jiménez-Ubieto A, Montes-Moreno S, López-Guillermo A, Caballero MD, Martín García-Sancho A. Rey-Búa B, et al. Among authors: jimenez ubieto a. Clin Cancer Res. 2024 Sep 3;30(17):3704-3714. doi: 10.1158/1078-0432.CCR-24-0183. Clin Cancer Res. 2024. PMID: 38900037 Clinical Trial.
New therapies for relapsed or refractory aggressive B-cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group.
Bastos-Oreiro M, Abrisqueta P, Gutierrez A, Jiménez Ubieto A, Poza M, Fernanez-Caldas P, LLacer MJ, Gonzalez de Villambrosia S, Córdoba R, López A, Ceballos E, Navarro B, Muntañola A, Donato E, Diez-Baeza E, Escoda L, Luzardo H, Peñarrubia MJ, García Belmonte D, Pardal E, Lozada C, Martín García-Sancho A. Bastos-Oreiro M, et al. Among authors: jimenez ubieto a. Hemasphere. 2024 Apr 22;8(4):e70. doi: 10.1002/hem3.70. eCollection 2024 Apr. Hemasphere. 2024. PMID: 38650598 Free PMC article. No abstract available.
Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study.
Bastos-Oreiro M, Gutierrez A, Cabero A, López J, Villafuerte P, Jiménez-Ubieto A, de Oña R, De la Fuente A, Navarro B, Peñalver J, Martínez P, Alonso C, Infante M, Córdoba R, Perez-Montero B, Pérez de Oteyza J, González de Villambrosio S, Fernández-Caldas P, Del Campo R, García Belmonte D, Diaz-Gálvez J, Salar A, Sancho JM. Bastos-Oreiro M, et al. Among authors: jimenez ubieto a. Cancers (Basel). 2024 Mar 26;16(7):1285. doi: 10.3390/cancers16071285. Cancers (Basel). 2024. PMID: 38610963 Free PMC article.
Author Correction: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
Sánchez R, Dorado S, Ruíz-Heredia Y, Martín-Muñoz A, Rosa-Rosa JM, Ribera J, García O, Jimenez-Ubieto A, Carreño-Tarragona G, Linares M, Rufián L, Juárez A, Carrillo J, Espino MJ, Cáceres M, Expósito S, Cuevas B, Vanegas R, Casado LF, Torrent A, Zamora L, Mercadal S, Coll R, Cervera M, Morgades M, Hernández-Rivas JÁ, Bravo P, Serí C, Anguita E, Barragán E, Sargas C, Ferrer-Marín F, Sánchez-Calero J, Sevilla J, Ruíz E, Villalón L, Del Mar Herráez M, Riaza R, Magro E, Steegman JL, Wang C, de Toledo P, García-Gutiérrez V, Ayala R, Ribera JM, Barrio S, Martínez-López J. Sánchez R, et al. Among authors: jimenez ubieto a. Sci Rep. 2024 Mar 28;14(1):7400. doi: 10.1038/s41598-024-57570-5. Sci Rep. 2024. PMID: 38548834 Free PMC article. No abstract available.
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A, Martín-Muñoz A, Poza M, Dorado S, García-Ortiz A, Revilla E, Sarandeses P, Ruiz-Heredia Y, Baumann T, Rodríguez A, Calbacho M, Sánchez PM, Pina JMS, García-Sancho AM, Figaredo G, Gil-Alós D, Rufián L, Rodríguez M, Carneros L, Martínez-Laperche C, Bastos-Oreiro M, Wang C, Cedena MT, Rapado I, de Toledo P, Gallardo M, Valeri A, Ayala R, Martínez-López J, Barrio S. Jiménez-Ubieto A, et al. Front Immunol. 2024 Jan 10;14:1349296. doi: 10.3389/fimmu.2023.1349296. eCollection 2023. Front Immunol. 2024. PMID: 38268917 Free PMC article.
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K, Vilmar A, Jerkeman M, Chen JMH, Ohler A, Stilgenbauer S, Thieblemont C, Lambert J, Zilioli VR, Sancho JM, Jimenez-Ubieto A, Fischer L, Eyre TA, Keeping S, Park JE, Wu JJ, Nunes A, Reitan J, Wade SW, Salles G. Hess G, et al. Among authors: jimenez ubieto a. Leuk Lymphoma. 2024 Jan;65(1):14-25. doi: 10.1080/10428194.2023.2268228. Epub 2024 Jan 10. Leuk Lymphoma. 2024. PMID: 37840282 Free article.
Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure.
Zamanillo I, Medina de Alba L, Gil R, de la Puerta R, Alonso R, Jimenez-Ubieto A, Cedena MT, Calbacho M, Ayala R, Martinez-Lopez J. Zamanillo I, et al. Among authors: jimenez ubieto a. Life (Basel). 2023 Aug 31;13(9):1841. doi: 10.3390/life13091841. Life (Basel). 2023. PMID: 37763245 Free PMC article.
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A, Martín-Muñoz A, Poza M, Dorado S, García-Ortiz A, Revilla E, Sarandeses P, Ruiz-Heredia Y, Baumann T, Rodríguez A, Calbacho M, Sánchez PM, Pina JMS, García-Sancho AM, Figaredo G, Rufián L, Rodríguez M, Carneros L, Martínez-Laperche C, Bastos-Oreiro M, Wang C, Cedena MT, Rapado I, de Toledo P, Gallardo M, Valeri A, Ayala R, Martínez-López J, Barrio S. Jiménez-Ubieto A, et al. Front Immunol. 2023 Aug 16;14:1243241. doi: 10.3389/fimmu.2023.1243241. eCollection 2023. Front Immunol. 2023. PMID: 37662957 Free PMC article.
54 results